2-bromo-N-(2,3-dichlorophenyl)acetamide | 349120-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-N-(2,3-dichlorophenyl)acetamide
• CAS: 349120-91-8
• 化学式: C₈H₆BrCl₂NO
• mdl: MFCD02974361
• 分子量: 282.952
• InChiKey: YFSBEKSZGIWPPL-UHFFFAOYSA-N

物化性质

• 沸点：
  396.5±42.0 °C(Predicted)
• 密度：
  1.772±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-bromo-N-(2,3-dichlorophenyl)acetamide 在 sodium azide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-azido-N-(2,3-dichlorophenyl)acetamide
  参考文献：
  名称：

  Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes

  摘要：

  GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142-mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.

  DOI：

  10.1021/acsmedchemlett.6b00314
• 作为产物：
  描述：

  2,3-二氯苯胺 、 溴乙酰溴 在 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 生成 2-bromo-N-(2,3-dichlorophenyl)acetamide
  参考文献：
  名称：

  吡唑-咪唑-三唑杂化物的简易合成、抗菌评价和分子对接研究

  摘要：

  摘要 一系列十八唑-咪唑-三唑杂化物(2-(4-((2-(取代-1H-吡唑-1-基)-4-苯基-1H-咪唑-1-基)甲基)-1H- 1,2,3-三唑-1-基)-N-(取代)苯基乙酰胺)(6a-6r)通过原位生成的2-叠氮基-N-取代乙酰胺和N-炔丙基化吡唑之间的点击反应合成咪唑衍生物依次由1-(1H-咪唑-2-基)-1H-吡唑和炔丙基溴区域选择性地获得。合成化合物 (6a-6r) 的结构通过各种光谱研究（1D 和 2D NMR、FT-IR、HRMS）得到证实，并评估了抗菌活性。化合物 6m 对黑曲霉表现出优异的效力（MIC 值为 0.0064 µmol/mL）；甚至优于参考药物氟康唑（MIC 值 0.0112 µmol/mL）。更多，

  DOI：

  10.1016/j.molstruc.2020.129216

文献信息

• Acetamides and benzamides that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20040029887A1

  公开（公告）日：2004-02-12

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。
• Discovery of 3-Methyl-<i>N</i>-(1-oxy-3‘,4‘,5‘,6‘-tetrahydro-2‘<i>H</i>-[2,4‘-bipyridine]-1‘-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D₄ Agonist for the Treatment of Erectile Dysfunction
  作者：Meena V. Patel、Teodozyj Kolasa、Kathleen Mortell、Mark A. Matulenko、Ahmed A. Hakeem、Jeffrey J. Rohde、Sherry L. Nelson、Marlon D. Cowart、Masaki Nakane、Loan N. Miller、Marie E. Uchic、Marc A. Terranova、Odile F. El-Kouhen、Diana L. Donnelly-Roberts、Marian T. Namovic、Peter R. Hollingsworth、Renjie Chang、Brenda R. Martino、Jill M. Wetter、Kennan C. Marsh、Ruth Martin、John F. Darbyshire、Gary Gintant、Gin C. Hsieh、Robert B. Moreland、James P. Sullivan、Jorge D. Brioni、Andrew O. Stewart

  DOI：10.1021/jm060662k

  日期：2006.12.1

  The goal of this study was to identify a structurally distinct D-4-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl) piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl) piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.
• Synthesis and evaluation of novel pyrazole-imidazole hybrids as antimicrobial candidates
  作者：Suman Punia、Vikas Verma、Devinder Kumar、Ashwani Kumar、Laxmi Deswal、Mahavir Parshad

  DOI：10.1080/00397911.2021.1953532

  日期：2021.9.17
• MacPherson, Iain S.; Kirubakaran, Sivapriya; Gorla, Suresh Kumar, Journal of the American Chemical Society, 2010, vol. 132, p. 1230 - 1231
  作者：MacPherson, Iain S.、Kirubakaran, Sivapriya、Gorla, Suresh Kumar、Riera, Thomas V.、D'Aquino, J. Alejandro、et al.

  DOI：——

  日期：——
• ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
  申请人：Abbott Laboratories

  公开号：EP1509213A2

  公开（公告）日：2005-03-02